Clinical Trials Browser

Phase 1/2 × Unknown × Multiple Myeloma × Clear all

NCT04499339 2024-04-25

A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT03975907 2024-03-12

Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

Phase 1/2 Unknown

Multiple Myeloma

NCT01754402 2024-02-20

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Phase 1/2 Unknown

56 enrolled 12 charts

Multiple Myeloma

NCT06223646 2024-01-25

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT04714827 2023-12-29

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT05280275 2023-12-01

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Phase 1/2 Unknown

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT06126237 2023-11-13

A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Amyloidosis, Multiple Myeloma

NCT04309981 2023-08-28

Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.

Phase 1/2 Unknown

Multiple Myeloma

NCT03090659 2023-06-12

LEGEND-2

Phase 1/2 Unknown

Multiple Myeloma

NCT05857982 2023-05-15

Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT05749133 2023-04-20

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Phase 1/2 Unknown

Multiple Myeloma

NCT04272151 2023-04-18

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04674514 2023-03-07

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT05739188 2023-02-23

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Phase 1/2 Unknown

Multiple Myeloma

NCT05672420 2023-01-05

Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies

Phase 1/2 Unknown

Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Hemorrhage, Infections, Leukemia, Lymphoma, Multiple Myeloma, Neutropenia, Thrombocytopenia, Hematologic Neoplasms

NCT04935580 2022-08-03

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Phase 1/2 Unknown

Multiple Myeloma

NCT05150522 2021-12-09

B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT05066646 2021-11-23

FUMANBA-1

Phase 1/2 Unknown

Multiple Myeloma

NCT03670173 2021-05-19

Safety and Efficacy Assessments of Osalmid in Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT04891744 2021-05-18

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Phase 1/2 Unknown

Multiple Myeloma

NCT03795597 2021-04-26

BuMelCarAuto

Phase 1/2 Unknown

Multiple Myeloma

NCT04762745 2021-02-21

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Recurrence

NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Phase 1/2 Unknown

CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

NCT03018405 2019-09-19

THINK

Phase 1/2 Unknown

GATA2 Deficiency, Multiple Myeloma

NCT03271632 2019-09-19

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT02954445 2019-06-25

A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies

Phase 1/2 Unknown

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma

NCT03940833 2019-05-07

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Phase 1/2 Unknown

Multiple Myeloma

NCT03767751 2018-12-07

A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT03607643 2018-07-31

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Phase 1/2 Unknown

CNSGastrointestinalPlasma cell

Colonic Neoplasms, Gallbladder Neoplasms, Glioblastoma, Liver Neoplasms, Multiple Myeloma, Pancreatic Neoplasms, Rectal Neoplasms

NCT01792102 2018-03-05

Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT03322735 2017-12-29

Study of BCMA CAR-T in Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT03091933 2017-12-06

GLIDE

Phase 1/2 Unknown

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02488382 2017-10-17

Lonquek for Autologous Stem Cell Mobilization

Phase 1/2 Unknown

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT02519114 2017-02-10

Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT01541332 2016-03-10

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT01886976 2016-01-28

CART-138

Phase 1/2 Unknown

Multiple Myeloma

NCT01812096 2015-08-18

MM

Phase 1/2 Unknown

Multiple Myeloma

NCT00800059 2015-07-27

TMI-ASCT

Phase 1/2 Unknown

Multiple Myeloma, Recurrence

NCT02145715 2015-06-26

MUKsix

Phase 1/2 Unknown

Multiple Myeloma

NCT02248402 2014-09-25

Vax-DC/MM

Phase 1/2 Unknown

Multiple Myeloma

NCT01435720 2014-09-11

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Phase 1/2 Unknown

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Leukemia, Plasma Cell, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT02007811 2014-03-26

B-cell therapy

Phase 1/2 Unknown

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00334932 2014-01-10

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

Phase 1/2 Unknown

Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

NCT01695590 2013-06-04

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01686386 2013-04-05

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Recurrence

NCT01010243 2012-05-30

MM03

Phase 1/2 Unknown

Multiple Myeloma, Recurrence

NCT00431990 2011-08-12

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Phase 1/2 Unknown

Multiple Myeloma